New Zealand reports first death linked to Pfizer Covid-19 vaccine

An independent Covid-19 vaccine safety monitoring board considered that the woman's death was due to myocarditis, which is known to be a rare side effect of the Pfizer Covid-19 vaccine

Pfizer Vaccine, Coronavirus vaccine
The Pfizer media team in New Zealand did not immediately reply to an emailed request for comment | Photo: Shutterstock
Reuters
2 min read Last Updated : Aug 31 2021 | 1:20 AM IST
New Zealand on Monday reported what authorities said was the country's first recorded death linked to the Pfizer Covid-19 vaccine.
 
The information was released by the health ministry following a review by an independent Covid-19 vaccine safety monitoring board of the death of a woman after receiving the vaccine. The ministry's statement did not give the woman's age.
 
The board considered that the woman's death was due to myocarditis, which is known to be a rare side effect of the Pfizer Covid-19 vaccine, the statement said. Myocarditis is an inflammation of the heart muscle that can limit the organ's ability to pump blood and can cause changes in heartbeat rhythms.
 
"This is the first case in New Zealand where a death in the days following vaccination has been linked to the Pfizer Covid-19 vaccine," the health ministry said.
 
The Pfizer media team in New Zealand did not immediately reply to an emailed request for comment.
 
The case has been referred to the coroner and the cause of death has not yet been determined, the health ministry said.
 
The independent board, however, did consider that the myocarditis was probably because of the vaccination.
 
The board also noted that there were other medical issues occurring at the same time which may have influenced the outcome following vaccination.
 
"The benefits of vaccination with the Pfizer Covid-19 vaccine continue to greatly outweigh the risk of both Covid-19 infection and vaccine side effects, including myocarditis," it added.
 
So far the Pfizer/BioNTech, Janssen and AstraZeneca vaccines have been provisionally approved by New Zealand authorities.
However, the Pfizer vaccine is the only vaccine that has been approved for rollout to the public.
 
New Zealand is battling an outbreak of the Delta variant of Covid-19 after nearly six months of being virus free.
It reported 53 new cases on Monday, taking the total number of infections in the current outbreak to 562.
 
A nationwide lockdown was enforced earlier this month to beat the spread of the Delta variant.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :New ZealandCoronavirus VaccinePfizer

Next Story